Biocon faces US patent infringement action from Impax over Rytary generic
MLex Summary: Indian generic drug manufacturer Biocon was hit with a complaint for patent infringement in the US District of New Jersey by Impax Laboratories over its Abbreviated New Drug Application...To view the full article, register now.
Already a subscriber? Click here to view full article